Despite new T2DM therapeutic options, such as GLP-1 RAs, there is still a need for therapies tailored to a patient’s compliance that are cost effective over the long-term and decrease unwanted side effects. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.